 |
|
Characteristics of the Sentinel Lymph Node in Breast Cancer Predict Further Involvement of Higher-Echelon Nodes in the Axilla
A Study to Evaluate the Need for Complete Axillary Lymph Node Dissection
Vidyulata J. Kamath;
Rosemary Giuliano, ARNP,MSN;
Emilia L. Dauway, MD;
Alan Cantor, PhD;
Claudia Berman, MD;
Ni Ni Ku, MD;
Charles E. Cox, MD;
Douglas S. Reintgen, MD
Arch Surg. 2001;136:688-692.
Background Sentinel lymph node (SLN) biopsy techniques provide accurate nodal staging for breast cancer. In the past, complete lymph node dissection (CLND) (levels 1 and 2) was performed for breast cancer staging, although the therapeutic benefit of this more extensive procedure has remained controversial.
Hypothesis It has been demonstrated that if the axillary SLN has no evidence of micrometastases, the nonsentinel lymph nodes (NSLNs) are unlikely to have metastases.
Objective To determine which variables predict the probability of NSLN involvement in patients with primary breast carcinoma and SLN metastases.
Methods An analysis of 101 women with SLN metastases and subsequent CLND was performed. Variables included size of the primary tumor, tumor volume in the SLN, staining techniques used to initially identify the micrometastases (cytokeratin immunohistochemical vs hematoxylin-eosin), number of SLNs harvested, and number of NSLNs involved with the metastases. Tumor size was determined by the invasive component of the primary tumor. Patients with ductal carcinoma in situ who were upstaged with cytokeratin staining were considered to have stage T1a tumors.
Results Sentinel lymph node micrometastases (<2 mm) detected initially by cytokeratin staining were associated with a 7.6% (2/26) incidence of positive CLND compared with a 25% (5/20) incidence when micrometastases were detected initially by routine hematoxylin-eosin staining. Sentinel lymph node micrometastases, regardless of identification technique, inferred a risk of 15.2% (7/46) for NSLN involvement. As the volume of tumor in the SLN increased (ie, <2 mm, >2 mm, grossly visible tumor), so did the risk of NSLN metastases (P<.001).
Conclusions Our study demonstrated that patients with micrometastases detected initially by cytokeratin staining had low-volume disease in the SLN with a small chance of having metastases in higher-echelon nodes in the regional basin other than the SLN. Characteristics of the SLN can provide information to determine the need for a complete axillary CLND. Complete lymph node dissection may not be necessary in patients with micrometastases detected initially by cytokeratin staining since the disease is confined to the SLN 92.4% of the time. However, the therapeutic value of CLND in breast cancer remains to be determined by further investigation.
From the Comprehensive Breast Cancer Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Surgery, University of South Florida, Tampa.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Characteristics of the Sentinel Lymph Node in Breast Cancer Predict Further Involvement of Higher-Echelon Nodes in the Axilla—Invited Critique
Kirby I. Bland
Arch Surg. 2001;136(6):692.
EXTRACT
| FULL TEXT
Archives of Surgery Reader's Choice: Continuing Medical Education
Arch Surg. 2001;136(6):712-713.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Comparison of Models to Predict Nonsentinel Lymph Node Status in Breast Cancer Patients With Metastatic Sentinel Lymph Nodes: A Prospective Multicenter Study
Coutant et al.
JCO 2009;27:2800-2808.
ABSTRACT
| FULL TEXT
Impact and Remaining Challenges in the Use of Sentinel Lymph Node Biopsy in Early-stage Breast Cancer
Lyman et al.
Am Soc Clin Oncol Ed Book 2009;2009:346-353.
ABSTRACT
| FULL TEXT
Micrometastases in Sentinel Lymph Node in a Multicentric Study: Predictive Factors of Nonsentinel Lymph Node Involvement--Groupe Des Chirurgiens De La Federation Des Centres De Lutte Contre Le Cancer
Houvenaeghel et al.
JCO 2006;24:1814-1822.
ABSTRACT
| FULL TEXT
Sentinel Node Micrometastases and Non-Sentinel Nodes in Breast Cancer: How Much Do We Need to Know?
Bear
JCO 2006;24:1788-1790.
FULL TEXT
An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes.
Abdul-Rasool et al.
J. Clin. Pathol. 2006;59:289-297.
ABSTRACT
| FULL TEXT
Case 35-2005 -- A 56-Year-Old Woman with Breast Cancer and Isolated Tumor Cells in a Sentinel Lymph Node
Davidson et al.
NEJM 2005;353:2177-2185.
FULL TEXT
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
Lyman et al.
JCO 2005;23:7703-7720.
ABSTRACT
| FULL TEXT
Axillary Sentinel Node and Tumour-related Factors Associated with Non-sentinel Node Involvement in Breast Cancer
Cserni et al.
Jpn J Clin Oncol 2004;34:519-524.
ABSTRACT
| FULL TEXT
Factors affecting metastases to non-sentinel lymph nodes in breast cancer
Fleming et al.
J. Clin. Pathol. 2004;57:73-76.
ABSTRACT
| FULL TEXT
Nonvisualization of Axillary Sentinel Node During Lymphoscintigraphy: Is There a Pathologic Significance in Breast Cancer?
Brenot-Rossi et al.
JNM 2003;44:1232-1237.
ABSTRACT
| FULL TEXT
Current Status of Sentinel Lymph Node Mapping and Biopsy: Facts and Controversies
Jakub et al.
The Oncologist 2003;8:59-68.
ABSTRACT
| FULL TEXT
|
